| |
Monday, 4 November 2002 |
|
8:00-9:45 |
Second Plenary Session
Willem Burger Zaal C3.2 |
| |
Integrating
Economic Arguments in Health Policy
Moderator: Frans Rutten PhD, ISPOR Annual
European Congress Chair & Professor of Health Economics, iMTA, Erasmus
University, Rotterdam, The Netherlands and The therapeutic Center “De
Viersprong”, Halsleren, The Netherlands
Risk-Sharing Between
Payer and Producer
Speaker: Adrian Towse MA, Mphil,
Director, Office of Health Economics, London, UK
This presentation will explore risk-sharing offers a potential route for
reconciling payer demands for cost-effectiveness evidence on product launch
with pharmaceutical industry concerns that cost-effectiveness can only be
assessed when there is experience of routine use of a product in clinical
practice. In particular, it will consider the theory and potential for
practical application of risk-sharing looking at examples including the UK
Multiple Sclerosis scheme.
Cost-effectiveness and Guidance
Speaker: Martin Buxton PhD, Professor, Health
Economics Research, Brunel University, Uxbridge, UK
Reconciliation of Economic Arguments and
Clinical Practice
Speaker: Jan Busschbach PhD, Senior
Investigator, Department of Medical Psychology and Psychotherapy, Erasmus
Medical Center, Rotterdam, The Netherlands & The Therapeutic Center “De
Viersprong,” Halsteren, The Netherlands
There is an increasing awareness that the cost-effectiveness ration is
interpreted in view of the magnitude of the burden of disease. For a low
burden of disease one is not willing to accept the same cost-effectiveness
ratio that seems appropriate in patients with a high burden. This is reason
why burden of disease is an important argument in reimbursement discussions
and the presentation will show how one can integrate both arguments. |
|
9:45-10:00 |
Break - Coffee Breaks
Sponsored by Caro Research |
|
10:00-11:00 |
Contributed Podium Presentations (4
Concurrent Topics) |
| |
|
Pharmacoeconomic/health economic,
quality-of-life and outcomes research study results for the following
disorders/diseases will be presented |
|
Cancer Studies Van Rijckevorsel Zaal C4.5 |
| |
Moderator: Arne Heissel PhD, Health
Outcomes Manager – Europe, Ethicon Endo-Surgery, Norderstedt, Germany |
|
CN1 |
A STOCHASTIC ECONOMIC EVALUATION OF
LETROZOLE VERSUS TAMOXIFEN AS A FIRST-LINE HORMONAL THERAPY FOR ADVANCED
BREAST CANCER IN POSTMENOPAUSAL PATIENTS IN GERMANY
Fricke FU1, Quednau K2, Pirk O1
1Fricke & Pirk GmbH, Nuremberg, Germany; 2Novartis Pharma GmbH,
Nuremberg, Germany |
|
CN2 |
ECONOMIC EVALUATION OF NEW POLY-CHEMOTHERAPY
REGIMENS AS ALTERNATIVES TO CISPLATIN PLUS PACLITAXEL IN ADVANCED
NON-SMALL CELL LUNG CANCER
Neymark N1, van Meerbeeck J2, Smit E2, Lianes P2, Giaccone G2
1EORTC, Brussels, Belgium; 2EORTC Lung Cancer Group, Brussels, Belgium
|
|
CN3 |
IMMUNOTHERAPY WITH AUTOLOGOUS TUMOR CELL-BCG
VACCINE (ONCOVAX®) IN PATIENTS WITH STAGE II COLON CANCER: MEDICAL AND
ECONOMIC BENEFITS
Uyl-de Groot CA1, Hanna MG2, Groot MT1, Verboom P1, Hoover HC3,
Vermorken JB4
1Erasmus University, Rotterdam, Netherlands; 2Intracel Corporation,
Rockville, MD, USA; 3Lehigh Valley Hospital, Allentown, PA, USA;
4Universitair Ziekenhuis Antwerpen, Antwerpen, Belgium |
Cardiovascular Diseases/Disorders Studies
Van Beuningen Zaal C3.5 |
| |
Moderator: Jeremy Chancellor MSc, Managing Director, European
Operations, Innovus Research (UK) Ltd, Amersham, UK |
|
CV1 |
COST-EFFECTIVENESS OF FONDAPARINUX VS ENOXAPARIN
AS PROPHYLAXIS AGAINST VENOUS THROMBOEMBOLISM FOLLOWING ORTHOPAEDIC
SURGERY
Posnett J, Gordois A
University of York, York, England |
|
CV2 |
ESTIMATION OF EXPENDITURES FOR CORONARY HEART
DISEASE (CHD) IN GERMANY
Wendland G
Consultant, Cologne, NW, Germany |
|
CV3 |
MULTI-COUNTRY COMPARISON OF HYPERTENSION
COSTS FROM HOSPITALIZATIONS AND AMBULATORY CARE
Mullins CD1, Sikirica M1, Seneviratne V1, Ahn J1, Akhras KS2
1University of Maryland, Baltimore, MD, USA; 2Pharmacia Corporation,
Skokie, IL, USA |
|
Infectious Disease - Session I Willem Burger Zaal C3.2 |
| |
Moderator: Peter G. Davey MD, FRCP,
2002-2003 ISPOR President & Head of Pharmacoeconomics, University of
Dundee, Dundee, Scotland, UK |
|
IN1 |
A BAYESIAN APPROACH TO
NET HEALTH BENEFITS: AN ILLUSTRATION AND APPLICATION TO MODELING HIV
PREVENTION
Johnson-Masotti A1, Laud P2, Hoffmann R2, Hayat M2, Pinkerton S2
1McMaster University, Hamilton, ON, Canada; 2Medical College of
Wisconsin, Milwaukee, WI, USA |
|
IN2 |
COST-EFFECTIVENESS
(CE) OF SCREENING DONATED BLOOD WITH MINIPOOL NUCLEIC ACID TESTING (NAT)
FOR HEPATITIS B VIRUS (HBV), HEPATITIS C VIRUS (HCV), AND HUMAN
IMMUNODEFICIENCY VIRUS (HIV)
Grima DT1, Marshall D1, Weinstein M2, Wong JB3, Kleinman S4, AuBuchon J5
1Innovus Research Inc, Burlington, ON, Canada; 2Harvard School of Public
Health, Boston, MA, USA; 3Tufts University School of Medicine, Boston,
MA, USA; 4Kleinman Biomedical Research, Victoria, BC, USA;
5Dartmouth-Hitchcock Medical Centre, Lebanon, NH, USA |
|
IN3 |
METHODS FOR ASSESSING
COSTS AND EFFECTS OF ANTIRETROVIRAL THERAPIES IN HIV: THE IMPACT OF
USING AN EXTENDED STUDY PERIOD
Bos JM1, Sprenger HG2, Hubben G1, Postma MJ1
1Groningen University Institute for Drug Exploration, Groningen,
Netherlands; 2University Hospital of Groningen, Groningen, Netherlands
|
|
Women’s Health/Diabetes Studies Plate Zaal C4.4 |
| |
Moderator: Diane Jacqueline Wild MSc,
Partner, Oxford Outcomes, Oxford, UK |
|
WD1 |
NHP AND 15D PERFORM
WELL IN ASSESSMENT OF THE HRQOL OF HEALTHY WOMEN WITH HORMONE
REPLACEMENT THERAPY
Sintonen H1, Ohinmaa A2, Johansson S3, Kainulainen P3, Apajasalo M3
1University of Helsinki, Helsinki, Finland; 2University of Alberta,
Edmonton, AB, Canada; 3Orion Pharma, Espoo, Finland |
|
WD2 |
PRE-TERM PREGNANCY
TERMINATIONS FOLLOWING EXPOSURE TO ANTIDEPRESSANTS: A META-ANALYSIS
Hemels MEH, Koren G, Lanctot KL, Einarson A, Einarson T
University of Toronto, Toronto, ON, Canada |
|
WD3 |
PATIENT PREFERENCE AND
WILLINGNESS-TO-PAY IN FIVE EUROPEAN COUNTRIES FOR HUMALOG MIX25 COMPARED
TO HUMULIN 30/70 FOR THE TREATMENT OF TYPE 2 DIABETES
Aristides M1, Weston A2, FitzGerald P2, LeReun C2, Schulz M3, Maniadakis
N4, Kielhorn A4
1M-TAG Limited, London, United Kingdom; 2M-TAG Pty Ltd, Sydney,
Australia; 3Merck Sharp & Dohme (Australia), Sydney, NSW, Australia;
4Eli Lilly and Company Limited, Surrey, United Kingdom |
|
|
11:00-11:15 |
Break |
|
11:15-12:15 |
Contributed Podium Presentations (4
Concurrent Topics) |
| |
Pharmacoeconomic/health economic, quality-of-life, outcomes research
methodology issues, health policy, adherence and health utility studies will
be presented. |
| |
Outcomes Research Methodology Issues –
Session I
Plate Zaal C4.4 |
| |
Moderator: Kerstin (Chris) Bingefors MSc, PhD, 2002-2003 ISPOR Board
of Directors, Associate Professor, Uppsala University & Research
Director, Biomedical Centre, Uppsala, Sweden |
|
MD1 |
THE EQUITY-EFFICIENCY TRADEOFF: WHAT IS THE SOCIAL
INTERPRETATION OF EQUITY?
Pickee S1, Stolk E1, Ament A2, Busschbach J1
1Erasmus University, Rotterdam, Netherlands; 2University of Maastricht,
Maastricht, Netherlands |
|
MD2 |
MEASURING HEALTH IMPACTS ON WORK PERFORMANCE:
COMPARING SUBJECTIVE AND OBJECTIVE REPORTS
Pransky G1, Finkelstein SN2, Berndt E2, Kyle MK3, Mackell J4, Tortorice
DL2
1Liberty Mutual Center for Disability Research, Hopkinton, MA, USA;
2Massachusetts Institute of Technology, Cambridge, MA, USA; 3Carnegie
Mellon University, Pittsburgh, PA, USA; 4Pfizer, Inc, New York, NY, USA
|
|
MD3 |
VALIDATING A DISEASE MODEL ACCORDING TO CRITERIA
OF EVIDENCE BASED MEDICINE
Schramm W1, Neeser K1, Erny-Albrecht K1, Mast O2, Pfahlert V2, Wenzel H2
1IMIB Institute Basel, Basel, Switzerland; 2Roche Diagnostics GmbH,
Mannheim, Germany |
|
Healthcare Policy Studies Van Beuningen Zaal C3.5 |
| |
Moderator: Mark Nuijten MD, MBA, 2002-2003 ISPOR Board of Directors
& Director of European Business Development, MEDTAP International, Jisp,
The Netherlands |
|
HP1 |
EFFICIENT PRODUCTION OF HEALTH BENEFITS:
COST-EFFECTIVENESS EVIDENCE AND UTILISATION OF HEALTH TECHNOLOGY IN THE
UK
Benedict Á, Hutton J
MEDTAP International Inc, London, United Kingdom |
|
HP2 |
HEALTH ECONOMIC EDUCATION IN ALLOCATION DECISIONS:
A PRE-TEST POST-TEST STUDY
Evans CJ
Mapi Values USA LLC, Boston, MA, USA |
|
HP3 |
A RISK-ADJUSTED LEAGUE TABLE OF EXPECTED RETURNS
Sendi P1, Al MJ2
1University of Basel, Basel, Switzerland; 2Erasmus University,
Rotterdam, Netherlands |
|
Adherence (Compliance) Studies Van
Rijckevorsel Zaal C4.5 |
| |
Moderator: Rod Taylor MSc, PhD, Senior Lecturer, Department of
Public Health & Epidemiology, University of Birmingham, Birmingham, UK |
|
CP1 |
CROSS-CULTURAL DIFFERENCES IN NON-ADHERENT
ATTITUDES
Bolge SC, McDonnell DD, Eschmann B, Annunziata K, Donohue JA
Consumer Health Sciences, Princeton, NJ, USA |
|
CP2 |
THE IMPACT OF VARYING DEGREES OF COMPLIANCE WITH
OSTEOPOROSIS MEDICATION ON FRACTURE RATES IN ACTUAL PRACTICE
Caro JJ1, Ishak KJ2, Huybrechts KF1, Naujoks C3
1Caro Research Institute, Concord, MA, USA; 2Caro Research, Dorval,
Quebec, Canada; 3Novartis Pharma AG, Basel, Switzerland |
|
CP3 |
CLAIMS BASED MEASURES OF DRUG TAKING COMPLIANCE
AMONG MEDICAID PATIENTS WITH SCHIZOPHRENIA: FEASIBILITY AND PREDICTIVE
UTILITY
Christensen DB, Guo JD
University of North Carolina, Chapel Hill, NC, USA |
|
Health Utility Studies - Session I Willem Burger Zaal C3.2 |
| |
Moderator: Patrick Marquis MD, MBA, Managing Director, Mapi Values,
Boston, MA, USA |
|
UT1 |
36 INTO 1 DOESN'T GO
Kind P
University of York, York, England |
|
UT2 |
THE TRANSFORMATION OF SOCIAL PREFERENCE WEIGHTS:
IMPLICATIONS FOR COST-EFFECTIVENESS
Cleemput I1, Kind P2, Kesteloot K1
1Catholic University Leuven, Leuven, Belgium; 2University of York, York,
United Kingdom |
|
UT3 |
ESTIMATING HEALTH UTILITY FROM A PHYSICAL FUNCTION
ASSESSMENT IN RHEUMATOID ARTHRITIS (RA) PATIENTS TREATED WITH ADALIMUMAB
(D2E7)
Boggs R, Sengupta N, Ashraf T
Abbott Laboratories, Abbott Park, IL, USA |
|
|
12:15-13:30 |
Lunch, Exhibits & Contributed Poster Presentations
– Session I
Willem Burger Foyer & Expo Hal |
|
13:30-14:30 |
Issues Panels (4 Concurrent
Panels) |
| |
THE BURDEN OF THE REIMBURSEMENT HURDLE
Willem Burger Zaal C3.2
Moderator: Michael Drummond PhD, Director,
University of York, Centre for Health Economics, York, UK
Panelists: Bengt Jonsson PhD, Professor,
Stockholm School of Economics, Stockholm, Sweden; Taina Irene Sirkia
PhD(Pharm), General Secretary, Pharmaceuticals Pricing Board, Valtioneuvosto,
Finland; Harry Kleintjens MBA, Senior Manager, Lilly Netherlands BV, Houten,
The Netherlands; Emilia Alves da Silva MD, Head of the Scientific & Economic
Information Department, InfarMed, Lisbon, Portugal; Carlos Gouveia Pinto
PhD, Associate Professor, Instituto Superior de Economia e Gestao,
Universidade Tecnica de Lisboa, Lisbon, Portugal
A growing number of jurisdictions are requesting cost-effectiveness data as
part of reimbursement decisions. This imposes additional costs on both
manufacturers and decision-makers. The objectives of this panel session are:
(i) to compare experiences from different countries; and (ii) to investigate
ways by which the burden can be minimized without seriously compromising the
decision-making process.
CRITERIA FOR REIMBURSEMENT DECISIONS
Van Beuningen Zaal C3.5
Moderator: Christopher Evans PhD, Project
Director, Mapi Values, Boston, MA, USA
Panelists: Lorenzo Mantovani EconD, MSc, DSc,
Head of Research, Center of Pharmacoeconomics, University of Milan, Milan,
Italy; Manouche Tavakoli PhD, Director of Pharmacoeconomic Research Center,
University of St. Andrews, Fife, Scotland, UK and Wil GM Toenders, The Dutch
National Health Insurance Council, Amstelveen, The Netherlands
Discussion about threshold CE-ratios, their analytic foundation and their
relevance to decision makers. Variations between countries on threshold
levels will be addressed.
MEASURING INDIRECT COSTS: RELEVANT TO DECISION-MAKERS? Van
Rijckevorsel Zaal C4.5
Moderator: Werner Brouwer PhD, Senior
Researcher, iMTA, Erasmus University, Rotterdam, The Netherlands
Panelists: Rob Balthussen PhD, Global Programme
on Evidence for Health Policy, World Health Organisation, Geneva,
Switzerland; John Hutton BSc, Bphil, Vice President of Operations, MEDTAP
International, London, UK; Peter Wahlqvist MSc, Health Economist,
AstraZeneca R&D, Molndal, Sweden
Normally, it is argued that economic evaluations should take the societal
perspective, incorporating all costs and effects regardless who experiences
them. This means that indirect costs (or productivity costs) should also be
included in the analysis. However, one may claim that indirect costs are
hardly relevant to health care decision makers, as they do not fall in the
health care sector or under the health care budget.
BAYESIAN STATISTICS: BARRIERS TO ACCEPTANCE BY
DECISION-MAKERS Plate Zaal C4.4
Moderator: Bryan Luce PhD, MBA, Senior Research
Leader and CEO, MEDTAP International, Bethesda, MD, USA
Panelists: Martin J Buxton PhD, Director,
Health Economics Research Group- Brunnel University, Uxbridge, UK and Tony
O'Hagan BBc, PhD, Professor of Statistics, University of Sheffield,
Sheffield, UK
This issue panel reviews the Bayesian statistical approach to developing and
presenting evidence for decision makers, the benefits of and barriers to
such an approach. |
|
14:30-15:00 |
Break |
|
15:00-16:00 |
Contributed Workshop
Presentations (8 Concurrent Workshops in 4 categories) |
| |
SESSION I |
| |
|
Outcomes
Research Methodology Issues |
|
WW1 |
CONTROLLING FOR BIAS IN RETROSPECTIVE DATABASE RESEARCH:
PROPENSITY SCORES AND INSTRUMENTAL VARIABLES Van Beuningen
Zaal C3.5
Huse D, Thompson D
Innovus Research, Inc, Medford, MA, USA |
|
WW2 |
THE USE OF
EXPERT OPINION IN PHARMACOECONOMICS: NECESSARY EVIL OR FATAL WEAKNESS?
Ruys Zaal C4.6
Caro JJ, Huybrechts KF, Lee KM, O'Brien JA
Caro Research Institute, Concord, MA, USA |
|
Cost Study Issues |
|
WW3 |
COMPARING
DIFFERENT METHODS FOR ASSESSING COSTS OF AVOIDED MORBIDITY: A CASE ON
VENOUS THROMBOEMBOLISM Plate Zaal C4.4
Annemans L1, Gabriel S2, Minjoulat-Rey M2
1Ghent University; HEDM, Meise, Belgium; 2Sanofi-Synthelabo, Bagneux, Fr |
|
WW4 |
ECONOMIC
EVALUATION OF INNOVATIVE VACCINES
Hudig Zaal C3.3
Kühnel UM1, Bos JM2, Postma MJ3
1Berna Biotech Ltd, Bern, Switzerland; 2Groningen University Institute
for Drug Exploration (GUIDE), Groningen, Netherlands; 3Groningen
University Institute for Drug Exploration/University of Groningen
Research Institute of Pharmacy (GUIDE/GRIP), Groningen, Netherlands
|
|
WW5 |
ISSUES IN
THE DESIGN AND ANALYSIS OF MULTI-NATIONAL CLINICAL TRIALS FOR ECONOMIC
EVALUATION
Willem Burger Zaal C3.2
Drummond MF1, Chancellor JV2
1University of York, York, United Kingdom; 2Innovus Research (UK) Ltd,
High Wycombe, Buckinghamshire, United Kingdom |
|
Quality of
Life/Patient-Reported Outcomes Study Issues |
|
WW6 |
FROM
PATIENT REPORTED OUTCOMES IN CLINICAL RESEARCH TO PATIENT-PERSPECTIVE
ASSESSMENT IN CLINICAL DECISION-MAKING: ISSUES IN THE DEVELOPMENT AND
VALIDATION OF PSYCHOMETRIC TOOLS DESIGNED FOR USE IN THE CLINICAL
SETTING
Van Rijckevorsel Zaal C4.5
Arnould B1, Girod I2, Marquis P3
1Mapi Values, Lyon, France; 2Mapi Values, Macclesfield, Cheshire, United
Kingdom; 3Mapi Values, Boston, MA, USA |
|
Healthcare Policy Development Issues |
|
WW7 |
IS IT
WORTH IT? PROBLEMS IN CREATING A COST-EFFECTIVENESS THRESHOLD FOR HEALTH
CARE DECISION-MAKING Schadee Zaal C3.4
Hutton J1, Benedict Á1, Mauskopf J2
1MEDTAP International Inc, London, United Kingdom; 2MEDTAP
International, Durham, NC, USA |
|
WW8 |
HOW
TRANSFERABLE TO OTHER CARE SETTINGS ARE THE RESULTS OF RCT’S OF SERVICE
DELIVERY?
Van der Vorm Zaal C4.3
Wells M1, Uyl-de Groot CA2, Davey PG1
1University of Dundee, Dundee, United Kingdom; 2Erasmus University,
Rotterdam, Netherlands |
|
|
16:00-16:15 |
Break |
|
16:15-17:15 |
Contributed Workshop
Presentations (8 Concurrent Workshops in 4 Categories) |
| |
|
SESSION II |
|
Outcomes
Research Methodology Issues |
WW9
|
CHALLENGES IN OUTCOMES RESEARCH IN
CHILDREN: ADHD AS AN EXAMPLE Van der Vorm Zaal C4.3
Veraart C1, Nuijten MJC2, Engelfriet PM2, Remak E3
1Eli Lilly, Houten, Netherlands; 2MEDTAP International, Jisp,
Netherlands; 3Medtap International, London, UK |
|
WW10 |
MAXIMIZING SCIENTIFIC
RIGOR IN RETROSPECTIVE DATABASE RESEARCH: FUNDAMENTALS OF
QUASI-EXPERIMENTAL STUDY DESIGN Schadee Zaal C3.4
Thompson D, Huse D
Innovus Research, Inc, Medford, MA, USA |
|
Cost Study Issues |
|
WW11 |
DISCOUNTING HEALTH
BENEFITS AND PUBLIC DECISION MAKING: SOME ELEMENTS TO THINK OF
Hudig Zaal C3.3
Annemans L1, Postma M2
1Ghent University; HEDM, MEISE, Belgium; 2Groningen University Institute
for Drug Exploration/University of Groningen Research Institute of
Pharmacy (GUIDE/GRIP), Groningen, Netherlands |
|
WW12 |
THE ABCS OF DRGS:
WHAT YOU NEED TO KNOW TO USE COSTS DERIVED FROM DIAGNOSIS RELATED GROUPS
(DRG) AND SIMILAR CLASSIFICATION SYSTEMS
Willem Burger Zaal C3.2
O'Brien JA
Caro Research Institute, Concord, MA, USA |
|
WW13 |
ECONOMIC EVALUATION
OF INFECTIOUS DISEASES: THE ROLE OF MODELING IN THE SUPPORT OF
DECISION-MAKING Van Rijckevorsel Zaal C4.5
Welte R1, Bos JM2, van Genugten M3, Klose T4, Postma M2
1University of Ulm, Ulm, Germany; 2Groningen University Institute for
Drug Exploration (GUIDE), Groningen, Netherlands; 3National Institute of
Public Health and the Environment, Bilthoven, Netherlands;
4GlaxoSmithKline, Munich, Germany |
|
Quality of Life Study Issues |
|
WW22 |
HEALTH-RELATED QUALITY OF LIFE OUTCOMES AND
THE EUROPEAN CENTRALISED DRUG REGULATORY PROCESS: POLICY, PROCESS AND
STRATEGY
Ruys Zaal C4.6
Szende A1, Lloyd A1, Kline Leidy N2, 1MEDTAP International, London, UK;
2MEDTAP International, Inc, Bethesda, MD, USA |
|
Healthcare Policy Development Issues |
|
WW15 |
HOW TO OPTIMIZE COMMUNICATION OF YOUR RESULTS:
ACHIEVING HIGH IMPACT COMMUNICATIONS
Plate Zaal
Crawford B1, Gray C2, Evans C1, Piercy J3, Arnould B4
1Mapi Values, Boston, MA, USA; 2Adelphi Medi Cine, Bollington, United
Kingdom; 3Mapi Values, Macclesfield, United Kingdom; 4Mapi Values, Lyon,
France |
|
WW16 |
USING OUTCOMES RESEARCH DATA TO SUPPORT PRODUCT
VALUE FOR GLOBAL PRICING AND REIMBURSEMENT Van Beuningen Zaal
C3.5
Noe LL1, Mayo KW2, Seal B2
1Ovation Research Group, Highland Park, IL, USA; 2Pharmacia Corporation,
Peapack, NJ, USA |
|
|
17.30-19.00 |
Exhibitors’ Wine & Cheese
Reception, Poster Presentations – Session II
Willem Burger Foyer & Expo Hal |
| |
Sponsored by MEDTAP International |
|
